Table 1 baseline characteristics of participants
Total (N = 406) | Placebo (n = 194) | Tirofiban (n = 212) | P value | |
|---|---|---|---|---|
Age, y | 69 (59–75) | 68(57–76) | 69(59–78) | 0.442 |
Male, n (%) | 179(44.1) | 86(44.3) | 93(43.9) | 0.079 |
Smoking, n (%) | 47(11.6) | 19(9.8) | 28(13.2) | 0.07 |
Medical history, n (%) | ||||
Coronary heart disease | 74(18.2) | 40(20.6) | 34(16) | 0.05 |
Atrial fibrillation | 261(64.3) | 124(63.9) | 137(64.6) | 0.082 |
Hypertension | 197(48.5) | 92(47.4) | 105(49.5) | 0.072 |
Hyperlipidemia | 39(9.6) | 15(7.7) | 24(11.3) | 0.064 |
Diabetes | 68(16.7) | 29(14.9) | 39(18.4) | 0.069 |
Ischemic stroke | 85(20.9) | 44(22.7) | 41(19.3) | 0.069 |
Prestroke antithrombolic history, n (%) | ||||
History antiplatelet | 41(10.1) | 19(9.8) | 22(10.4) | 0.128 |
History anticoagulation | 63(15.5) | 31(16.0) | 32(15.1) | 0.106 |
Baseline SBP, mmHg | 148 (132–166) | 147 (131–164) | 150 (133–169) | 0.433 |
Serum glucose | 7.0 (5.6–9.2) | 7.0 (5.5–9.1) | 7.0 (5.6–9.3) | 0.9 |
Occlusion site, n (%) | 0.061 | |||
ICA intracranial | 101(24.9) | 49(25.3) | 52(24.5) | |
MCA-M1 | 239(58.9) | 114(58.8) | 125(59) | |
MCA-M2 | 66(16.3) | 31(16) | 35(16.5) | |
Substantial reperfusion, n (%) | 386(95.1) | 183(94.3) | 203(95.8) | 0.146 |
Anesthesia, n (%) | 0.087 | |||
General | 105(25.9) | 49(25.3) | 56(26.4) | |
Local | 301(74.1) | 145(74.7) | 156(73.6) | |
Baseline NIHSS | 16 (12–19) | 15 (11–18) | 16 (12–20) | 0.076 |
Baseline ASPECTS | 8 (7–9) | 8 (7–9) | 8 (7–9) | 0.456 |
Onset to randomization, min | 334(223–505) | 313(203–483) | 350(236–527) | 0.045 |
Onset to recanalization, min | 389(280–577) | 359(268–546) | 405(289–587) | 0.054 |
Total passes | 2 (2–3) | 2 (1–3) | 2 (2–3) | 0.051 |
ASITN-SIR | 2 (2–3) | 2 (2–3) | 2 (2–3) | 0.508 |